• Taylor M, Filby A. Health Impact Analysis of Cisplatin, Carboplatin and Oxaliplatin: Quantifying the health impact of platinum compounds. Johnson Matthey Technol. Rev., 2017, 61, (1), 32.
    • Mahon J, Claxton L, Wood H. Modelling the Cost-effectiveness of Human Milk and Breastfeeding in Preterm infants in the United Kingdom. Health Econ Rev. 2016 Dec;6(1):54. Epub 2016 Dec 1.
    • Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. Pharmacoeconomics. 2016 Oct 27.
    • Green W, Taylor M. Cost-effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes Ther. 2016 Sep;7(3):511-25.
    • Claxton L, Taylor M, Kay E. Oral Health Promotion: the Economic Benefits of Sugarfree Gum in the UK. Br Dent J. 2016, Feb 12; 220: 121–27.
    • Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil Zufarovich A. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ. 2014 Nov;24:1-11.
    • Claxton L, Malcolm B, Taylor M, Haig J, Leteneux C. Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging 2014 Nov;31(11):837-48.
    • Barnett JH, Lewis L, Blackwell AD, Taylor MJ. Early Intervention in Alzheimer’s Disease: A Health Economic Study of the Effects of Diagnostic Timing. BMC Neurol 2014 May 7;14(1):101.
    • Ronaldson S, Taylor MJ, Bech PG, Shenton R, Bufe A. Economic Evaluation of SQ-Standardized Grass Allergy Immunotherapy Tablet (Grazax®) in Children. Clinicoecon Outcomes Res 2014 April;6:187-196.
    • Lobotesis K, Veltkamp R, Carpenter IH, Claxton LM, Saver JL, Hodgson R. Cost-effectiveness of Stent-Retriever Thrombectomy in Combination with IV t-PA Compared with t=PA Alone for Acute Ischemic Stroke in the UK. J Med Econ. 2016:1-10.
    • Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil Zufarovich A. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ. 2014;24:1-11.
    • Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil Zufarovich A. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ. 2014;24:1-11.
    • Claxton L, Malcolm B, Taylor M, Haig J, Leteneux C. Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging. 2014;31(11):837-48.
    • Barnett JH, Lewis L, Blackwell AD, Taylor MJ. Early Intervention in Alzheimer’s Disease: A Health Economic Study of the Effects of Diagnostic Timing. BMC Neurol. 2014;14:101.
    • Ronaldson S, Taylor MJ, Bech PG, Shenton R, Bufe A. Economic Evaluation of SQ-Standardized Grass Allergy Immunotherapy Tablet (Grazax®) in Children. Clinicoecon Outcomes Res. 2014 ;8;6:187-96.
    • Taylor M, Serbetci E, Ferreira A, Gairy K, Lewis L, Blouin J, Mitchelle P. A United Kingdom-based Economic Evaluation of Ranibizumab for Patients with Retinal Vein Occlusion (RVO). J Med Econ. 2014;17(6):423-34.
    • Filby A, Lewis L, Taylor M. PH56 An Economic Evaluation of Interventions to Improve the Uptake of Vitamin D Supplements in England and Wales. NICE Guidance 2014, Mar.
    • Green W, Hutton J.  Health Technology Assessments in England: An Analysis of the NICE Medical Technologies Evaluation Programme.  European Journal of Health Economics 2013 15(5): 449-452.
    • Darba J, Kaskens L, Abecassis M, Carrasco J, Vitorino R, Taylor MJ.  Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide cronica resistente a la dosis estandar de imatinib en Portugal.  Pharamacoecon Span Res Artic.  Published online 20 December 2013.
    • Chaplin S, Jenks M, Craig JA.  Warfarin Monitoring: Economic Evaluation of Point-of-Care Tests Compared to Clinic Settings.  Journal of Medical Economics.  Published online 19 December 2013.
    • Burke M, Hacking N, Wright M, Iqbal K, Craig J.  Economic evaluation of early TIPS procedures with ePTFE covered stent-grafts compared to endoscopic procedures to manage acute variceal bleeding.  Journal of Hepatology 2013;58 (Supplement 1):S 252.
    • Dignan FL, Potter MN, Ethell ME, Taylor MJ, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, Shaw BE. High Readmission Rates are Associated with a Significant Economic Burden and Poor Outcome in Patients With Grade III/IV Acute GvHD. Clin Transplant. 2013 Jan-Feb;27(1):E56-63.
    • Hex N, Bartlett C, Wright DL, Taylor MJ, Varley D.  Estimating the Current and Future Costs of Type 1 and Type 2 Diabetes in the UK, including Direct Health Costs and Indirect Societal and Productivity Costs.  Diabetic Medicine 2012, 29 (7):855-862.
    • Delea TE, Rotter J, Taylor MJ, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ.  Cost-effectiveness of Zoledronic Acid vs Clodronic Acid for Newly-diagnosed Multiple Myeloma from the United Kingdom Healthcare System Perspective. J Med Econ 2012;15(3):454-64.
    • Burke MJ, Saxby RC, Taylor MJ.  The Economics of Screening Infants at Risk of Hearing Impairment: An International Analysis.  International Journal of Pediatric Otorhinolaryngology 2012; 76 (2):212-218.
    • Hutton J.  Health Economics” and the Evolution of Economic Evaluation of Health Technologies.  Health Economics 2012; 21:13-18.
    • Taylor MJ, Leonardi-Bee J, Agboola S, McNeill A, Coleman T.  Cost Effectiveness of Interventions to Reduce Relapse to Smoking Following Smoking Cessation.  Addiction 2011, 106: 1819-1826.
    • NICE Guidance. PH26 Smoking cessation during pregnancy; Tobacco Harm reduction June 2010.
    • Remak E, Manson S, Hutton J, et al. Cost-effectiveness of the endeavour stent in de novo native coronary artery lesions updated with contemporary data. Eurointervention. 2010; 5(7): 826-832.
    • Trueman P, Whitehead S. The economics of pressure relieving surfaces: an illustrative case study of the impact of high-specification surfaces on hospital finances. International Wound Journal. 2010; 7(1): 48-54.
    • Taylor M , Scuffham P, Chaplin S, Papo N. An economic evaluation of Valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.  Value in Health. 2009; 12(4): 459-465.
    • Trueman P, Hurry M, Bending M, Hutton J. The feasibility of harmonizing health technology assessments across jurisdictions: a case study of drug eluting stents. International Journal of Technology Assessment in Health Care. 2009; 25(4): 455-462.
    • Taylor MJ, Scuffham PA.  Pharmacoeconomic benefits of dasatinib in chronic myelogenous leukaemia.  Expert Review of Pharmacoeconomics and Outcomes Research 2009: 9(2); 117-121.
    • Taylor MJ. What is sensitivity analysis?  What Is. Series.  Hayward Medical Communications 2009.
    • Taylor MJ. UK economic evaluation and vaccination policy. Vaccines in Practice. 2009, 2(3)
    • NICE Guidance. PH10 Smoking cessation services Feburary 2008.
    • Hutton J, Trueman P, Facey K.  Harmonization of evidence requirements for health technology assessment in reimbursement decision making.  International Journal of Technology Assessment in Health Care 2008, 24(4): 511-517.
    • Trueman P, Taylor MJ, Twena N, Chubb B.  The Cost of Needlestick Injuries associated with Insulin Administration.  British Journal of Community Nursing 13 (9) 413-417, September 2008.
    • Trueman P. Cost-effectiveness Considerations for Home Health V.A.C®.Therapy in the United States of America and its Potential International Application.  International Wound Journal 5 (s2), 23-26, 2008.
    • Trueman P, Flack S, Loonstra A, Hauser T.  The Feasibility of Using V.A.C.® Therapy in Home Care Patients with Surgical and Traumatic Wounds in the Netherlands.  International Wound Journal 5 (2), 225–231, 2008.
    • Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA.  An Economic Evaluation of Sevelamer in Patients New to Dialysis.  Current Medical Research and Opinion, 2008; 24(2): 601-608.
    • Flack S, J Apelqvist, M Keith, P Trueman, D Williams.  An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers.  Journal of Wound Care, Vol. 17, Iss. 2, 31 Jan 2008, pp 71 – 78.
    • Hutton J, Trueman P, Henshall C.  Coverage with Evidence Development: An Examination of Conceptual and Policy Issues.  International Journal of Technology Assessment in Health Care, 2007, 23(4); 425-435.
    • Knopf K.B, Hutton J, Value and use of economic evaluation in oncology, J Clinical Oncology, December 2007; 25(35): 5666-5667.
    • Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis.  Value Health. 2007 Sep-Oct;10 (5):336-47.
    • Taylor MJ, Scuffham PA, McCollam P, Newby D.  Acute Coronary Syndromes in Europe: One-year costs and outcomes.  Current Medical Research and Opinion, 2007; 23 (3), 495-503.
    • Home P, Bagust A, Taylor MJ, Ambery P, Mendes da Costa S. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007, 25 (9) 801-802.
    • Téot L, Cherry G, Denis C, Dervaux B, Duncan G, Gottrup F, Harding K, Kerihuel JC, Lautenberg A, Mani R, Meaume S, Messina R, Morris S, Orsted H, Pavlovic M, Peter R, Ricci E, Sibbald G, Sussmann G, Trueman P; World Union of Wound Healing Societies.Reimbursement of dressings: a WUWHS statement. Int Wound J. 2006 Dec;3(4):296-301.
    • Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Tam T, Trueman P, Watkins J, Wilson A. Principles of Good Practice for Budget Impact Analysis.  Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis.  September 2006.
    • Trueman, Paul, and John Posnett. “What price wound care?” International Journal of Lower Extremity Wounds 5.4 (2006): 230.
    • Beale SJ, Bagust A, Shearer A, Martin A, Hulme L.  Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK.  PharmacoEconomics 2006; 24: 20 -34.
    • Meszaros A & Taylor MJ.  Determining the Factors that Contribute Towards NICE Decision Making: A binary choice model.  June 2006.
    • Bagust A, Evans M, Beale SJ, Home PD, Perry AS, Stewart M.  A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies.  PharmacoEconomics 2006; 24: 5-19.
    • Davies A, Hutton J, O’Donnell J, Kingslake S. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. British Journal of Cardiology. 2006, 13(3); 196-202.
    • Hutton J, McGrath C, Frybourg JM, Tremblay M, et al. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). International Journal of Technology Assessment in Health Care. 2006, 22 (1); 1-9.
    • Spencer A, Chilton SM, Covey J, Taylor MJ.  Testing the Internal Consistency of the Lottery Equivalent Method Using Health Outcomes: A Comment to Oliver.  Health Econ. 14: 161–167 (2005).
    • Bagust A, Beale SJ.  Modelling EuroQol Health-related Utility Values for Diabetic Complications from CODE-2 Data.  Health Economics 2005; 14: 217-230.
    • Aguiar-Ibanez R, Nixon J, Glanville J, Craig D, Rice S, Christie J, Drummond MF. Economic evaluation databases as an aid to healthcare decision makers and researchers. Expert Review of Pharmacoeconomics & Outcomes Research. 2005, 5 (6) 721-732.
    • Taylor MJ.  The Measurement of Health Improvements: An alternative to QALYs Gained.  November 2004.
    • Bagust A, Beale SJ.  Deteriorating Beta-Cell Function in Type 2 Adults: A Long Term Model.  Quarterly Journal of Medicine 2003; 96: 281-288.
    • Scuffham PA, Carr LM.  An Economic Evaluation of Continuous Subcutaneous Insulin Infusion Pumps Compared with Multiple Daily Injections.  Diabetic Medicine 2003; vol: 20; 586-593.
    • Gordois A, Scuffham PA, Warren E, Ward S.  “The Cost-effectiveness of Glivec for the Treatment of Accelerated and Blast Phases of Chronic Myeloid Leukaemia”.  British Journal of Cancer 2003; Vol 89 (4): 634-40.
    • Gordois A, Scuffham PA, Shearer A, Oglesby A.  “The Costs and Consequences of Peripheral Neuropathy in the UK”.  The Diabetic Foot 2003; Vol 6:1; 30-37.
    • Scuffham PA.  “Estimating Influenza-Related Hospital Admissions in Children and Adults:  A Time-Series Analysis”.  Disease Management and Health Outcomes 2003; Vol 11:4; 259-269.
    • Scuffham PA, Chaplin S, Legood R.  “The Incidence and Costs of Accidental Falls in Older People in the UK”.  Journal of Epidemiology and Community Health 2003; Vol 57; 740-744.
    • Bagust A, Schoeffski O, Shearer A, Goertz A, Reitberger U, Behrens M. The DiDACT economic model of type 2 diabetes for Germany. Diabetes und Stoffwechsel. 2002. 12(Suppl 1); 159.
    • Bagust A, Shearer A, Schoeffski O, Reitberger U, Goertz A, Behrens M. Cost-effectiveness in Germany of rosiglitazone-metformin combination in type 2 diabetes. Diabetologia. 2003, 46 (supple 2); A444.
    • Gordois A, Scuffham PA, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United Kingdom and the United States. Diabetes. 2003, 52 (Suppl 1); A185-186.
    • Scuffham PA, Legood R, Wilson E, Martin-Kennedy T.  “The Cost of Accidental Falls Associated with Visual Impairment” Visual Impairment Research 2002; Vol 4:1; 1-14.
    • Scuffham PA, Taylor MJ.  Economics and Decisions to End Life: van Acht and Stooker revisited.  Applied Health Economics and Health Policy 2002: 1(3); 123-128.
    • Taylor MJ. Scuffham PA. New Zealand bicycle helmet law: do the costs outweigh the benefits? Injury Prevention. 2002, 8; 317-320.

    View other recent publications page from YHEC